Vendor, Philadelphia, PA
The Institute for Cancer Research
UEI FF1XVJMDYVR1, CAGE 1RAF4
9 awards and $746,940 obligated between January 17, 2024 and July 21, 2026, 89% under full and open competition, against 2.9 offers on average where reported. 7 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 8 |
| Competed Under SAP | 1 |
| Delivery Order | 6 |
| Purchase Order | 1 |
Hear when The Institute for Cancer Research wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts The Institute for Cancer Research holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 4
- Obligated so far
- $517,832
- Soonest
- November 17, 2026
The 4 contracts, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to National Institutes of Health, by dollars.
| Fisher Bioservices Inc.Rockville, MD | $101,554,099 |
| PPD Development LPWilmington, NC | $65,307,629 |
| Seattle Children'S HospitalSeattle, WA | $61,525,979 |
| Alpha Genesis Inc.Yemassee, SC | $55,645,143 |
| Psychogenics Inc.Paramus, NJ | $36,035,836 |
| Rho Federal Systems Division Inc.Durham, NC | $35,268,211 |
Solicitations it won
SAM.gov opportunities whose award USAspending attributes to this vendor.
- PREVENT IDIQ MATO RFP
National Institutes of Health, NIH NCI
Award noticeNAICS 541714Philadelphia, PA75N91024D00003Awarded to The Institute for Cancer Research for $149,995,000
Posted Jan 31, 20242 publications
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91022F00001Delivery Order, August 29, 2024, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomakers Task Order Title: VaccineNAICS 541714, PSC AN12 | $515,612 |
| 75N91022F00003Delivery Order, February 26, 2024, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Task Order Title: Microbial Metabolite Mimicry, a Nano-Drug for Colon Cancer Prevention Prevent Preclinical Drug Development Program: PrecliNAICS 541714, PSC AN12 | $245,908 |
| 75N91022F00002Delivery Order, January 17, 2024, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Task Order TitlNAICS 541714, PSC AN12 | $2,220 |
| 75N91020F00001Delivery Order, February 9, 2024, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers to Title: Preventing Lung Cancer by NAICS 541714, PSC AN12 | $0 |
| 75N91023F00001Delivery Order, January 29, 2026, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Colorectal Cancer (Crc) Prevention by Urolithin a in Rodent CRC ModelsNAICS 541714, PSC AN12 | $0 |
| 75N91023F00003Delivery Order, April 7, 2026, Full and Open Competition, 1 offers | NIH NCINational Institutes of Health | Prevent Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarkers Task Order Title: Sulforaphane for the PrevenNAICS 541714, PSC AN12 | $0 |
| 75N91019D00022July 21, 2026, Full and Open Competition, 9 offers | NIH NCINational Institutes of Health | Eo 14398 Prevent Preclinical Efficacy and Intermediate Endpoint BiomarkersNAICS 541714, PSC AN12 | $0 |
| 75N91024D00003January 24, 2024, Full and Open Competition, 9 offersSolicitation | NIH NCINational Institutes of Health | Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ Contract in Support of the Prevent Cancer Preclinical Drug Development ProgramNAICS 541714, PSC AN12 | $0 |
| 75N92E21P00142Purchase Order, July 6, 2026, Competed Under SAP, 2 offers | National Institutes of Health NhgriNational Institutes of Health | The Elnitski Lab Is Purchasing Normal, Liver, and Prostate Cancer Patient Plasma.[21-004028]NAICS 541715, PSC 6505 | -$16,800 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research6505 Drugs and Biologicals
- Transactions
- 22 across 9 awards